Kite Pharma (KITE): CAR T Checks Show Physicians To Be Cautiously Optimistic - Jefferies

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after attending the Lymphoma & Myeloma meeting where current treatment landscapes and future therapies that included CAR T were discussed.

The analyst believes physicians remain cautiously optimistic on CAR T therapies overall and are excited by the impressive data to date. Many physicians the analyst spoke with are looking forward to more mature data (e.g., durability data) to ultimately determine how CAR T fits into each indication's treatment landscape.

No change to the price target of $72.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $49.30 yesterday.

You May Also Be Interested In

• Jefferies Downgrades ULTA Salon (ULTA) to Hold, 'Competition Intensifying & Prestige Refresh Needed'
• Comerica (CMA) PT Raised to $57 at DA Davidson
• Wolfe Research Upgrades Bank of America (BAC) to Outperform, 'Underearning Firms Shouldn’t Trade at a Discount'